Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution

Journal of Controlled Release

Volumn 145, Issue 1, 2010, Pages 49-57

  Tosi, G ^a   Vergoni, A V ^a   Ruozi, B ^a   Bondioli, L ^a   Badiali, L ^a   Rivasi, F ^a   Costantino, L ^a   Forni, F ^a   Vandelli, M A ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Brain delivery; Glycopeptides; In vivo experiments; Nanoparticles; Sialic acid

Indexed keywords

ANALGESIC ACTIVITY; BIODISTRIBUTIONS; BLOOD-BRAIN BARRIER; BRAIN DELIVERY; BRAIN PARENCHYMA; BRAIN RECEPTORS; CENTRAL NERVOUS SYSTEMS; FLUORESCENT MICROSCOPY; GLYCOPEPTIDES; IN-VIVO; IN-VIVO EXPERIMENTS; LONG LASTING; LOPERAMIDE; MODEL DRUGS; OPIOID DRUGS; PHARMACOLOGICAL EFFECTS; PLGA NANOPARTICLES; POLYMERIC NANOPARTICLES; SIALIC ACIDS; SURFACE-MODIFIED;

ACIDS; CARBOXYLIC ACIDS; EVOLUTIONARY ALGORITHMS; EXPERIMENTS; LIVER; NANOPARTICLES; PEPTIDES;

BRAIN;

BRAIN RECEPTOR; DRUG CARRIER; GLYCOPEPTIDE; LOPERAMIDE; NANOPARTICLE; PEPTIDE DERIVATIVE; POLYGLACTIN; POLYMERIC NANOPARTICLE; SEMILOPIOID PEPTIDE; SIALIC ACID; SIALIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN; BRAIN PARENCHYMA; CENTRAL NERVOUS SYSTEM; CONFOCAL MICROSCOPY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG TARGETING; EXPERIMENTAL ANIMAL; FLUORESCENCE MICROSCOPY; KIDNEY; LIVER; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SPLEEN; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; DRUG CARRIERS; GLYCOPEPTIDES; LACTIC ACID; LOPERAMIDE; MALE; MICROSCOPY, ELECTRON, SCANNING; N-ACETYLNEURAMINIC ACID; NANOPARTICLES; ORGAN SPECIFICITY; PAIN; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; RATS, INBRED STRAINS; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 77953478343     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.03.008     Document Type: Article

References (44)

1. Tosi G., Costantino L., Ruozi B., Forni F., Vandelli M.A. Polymeric nanoparticles for the drug delivery to the central nervous system. Exp. Opin. Drug Deliv. 2008, 5:155-174.
2. Ambruosi A., Khalansky A.S., Yamamoto H., Gelperina S.E., Begley D.J., Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Target. 2006, 14:97-105.
3. Lockman P.R., Oyewumi M.O., Koziara J.M., Roder K.E., Mumper R.J., Allen D.D. Brain uptake of thiamine-coated nanoparticles. J. Control. Release 2003, 93:271-282.
4. Tosi G., Costantino L., Rivasi F., Ruozi B., Leo E., Vergoni A.V., Tacchi R., Bertolini A., Vandelli M.A., Forni F. Targeting the central nervous system. In vivo experiments with peptide derivatized nanoparticles loaded with Loperamide and Rhodamine 123. J. Control. Release 2007, 122:1-9.
5. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl Acad. Sci. USA 1996, 93:14164-14169.
6. Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 1997, 14:325-328.
7. Ambruosi A., Yamamoto H., Kreuter J. Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J. Drug Target. 2005, 13:535-542.
8. Steiniger S.C.J., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., Severin S.E., Uhl R., Kock M., Geiger K.D., Gelperina S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 2004, 109:759-767.
9. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 1999, 16:1564-1569.
10. Friese A., Seiller E., Quack G., Lorenz B., Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 2000, 49:103-109.
11. Costantino L., Gandolfi F., Tosi G., Rivasi F., Vandelli M.A., Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood brain barrier. J. Control. Release 2005, 108:84-96.
12. Vergoni A.V., Tosi G., Tacchi R., Vandelli M.A., Bertolini A., Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine: NBM 2009, 5:369-377.
13. Bondioli L., Costantino L., Ballestrazzi A., Lucchesi D., Boraschi D., Pellati F., Benvenuti S., Tosi G., Vandelli M.A. PLGA nanoparticles surface-decorated with the sialic acid, N-acetylneuraminic acid. Biomaterials 2010, 31(12):3395-3403.
14. Crocker P.R., Hartnell A., Munday J., Nath D. The potential role of sialoadhesin as macrophage recognition molecule in health and disease. Glycoconj. J. 1997, 14:601-609.
15. Kelm S., Brossmer R., Isecke R., Gross H.J., Srenge K., Schauer R. Functional gropus of sialic acid involved in binding to siglecs (sialoadhesins) deduced from interaction with synthetic analogues. Eur. J. Biochem. 1998, 255:663-672.
16. Jain S., Hreczuk-Hirst D., Laing P., Gregoriadis G. Polysialylation: the natural way to improve the stability and pharmokinetics of protein and peptide drugs. Drug Del. Systems Sci. 2004, 4:59-65.
17. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 2006, 1:297-315.
18. Garcia-Garcia E., Andrieux K., Gil S., Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?. Int. J. Pharm. 2005, 298:274-292.
19. Castro D.J., Haghighat S., Saxton R.E., Reisler E., Jongwaard N., Castro D.J., Ward P.H., Lufkin R.B. Biodistribution of Rhodamine-123 in nude mice heterotransplanted with human squamous cell carcinomas. Laryngoscope 1992, 102:868-874.
20. de Lange E.C., de Bock G., Shinkel A.H., de Boer A.G., Breimer D.D. BBB transport using MDR 1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of Rhodamine-123. Pharm. Res. 1998, 15:1657-1665.
21. Harapanhalli R.S., Roy A.M., Aldestein S.J., Kassis A.I. [125I/127I/131I] Iodorhodamine: synthesis, cellular localization and biodistribution in athymic mice bearing human tumor xenografts and comparison with [99mTc]-Hexakis-(2-methoxyisobutylisonitrile). J. Med. Chem. 1998, 41:2111-2117.
22. Sweatman T.W., Seshadri R., Israel M. Metabolism and elimination of Rhodamine-123 in the rat. Cancer Chemother. Pharmacol. 1990, 27:205-210.
23. Costantino L., Gandolfi F., Bossy Nobs L., Tosi G., Gurny R., Rivasi F., Vandelli M.A., Forni F. Nanoparticulate drug carriers based on hybrid poly(d, l-lactide-co-glycolide)-dendron structures. Biomaterials 2006, 27:4635-4645.
24. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 1989, 55:R1-R4.
25. Chen H., Gaul F., Gou D., Maycock A. Determination of loperamide in rat plasma and bovine serum albumin by LC. J. Pharm. Biomed. Anal. 2000, 22:555-561.
26. Iqbal T., Kinjo M., Dowling T.C. Determination of Rhodamine-123 in cell lysate by HPLC with visible wavelength detection. J. Chrom. B. 2005, 184:259-262.
27. Eddy N.B., Leimbach D. Synthetic analgesic. II. Dithienylbutyl and dithienylbutylamines. J. Pharm. Exper. Ther 1953, 107:385-395.
28. Rezayat M., Rahnavard A., Zarrindast M. Role of cholecystokinin receptors in induction of antinociception in hot-plate test. Pharmacol. Toxicol. 2000, 87:58-62.
29. Xu Z., Pilch D.S., Srinivasan A.R., Olson W.K., Geacintov N.E., Breslauer K.J. Modulation of nucleic acid structure by ligand binding induction of a DNA RNA DNA hybrid triplex by DAPI intercalation. Bioorg. Med. Chem. 1997, 5:1137-1147.
30. Michaelis K., Hoffmann M.M., Dreis S., Herbert E., Alyautdin R.N., Michaelis M., Kreuter J., Langer K. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharm. Exp. Ther. 2006, 317:1246-1253.
31. Middleton J.C., Tipton A.J. Synthetic biodegradable polymers as medical devices. Med. Plast. Biomater. March 1998, 30-40.
32. Li S.M., Garreau H., Vert M. Structure-property relationships in the case of the degradation of massive poly(a-hydroxy acids) in aqueous media. Part 2: degradation of lactide-glycolide copolymers: PLA37.5 GA25 and PLA75GA25. J. Mater. Sci. Mater. Med. 1990, 1:131-139.
33. Fernandes A.I., Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int. J. Pharm. 2001, 217:215-224.
34. Egrie J.C., Browne J.K. Development and characterization of novel erythpoiesis stimulating protein (NESP). Br. J. Cancer 2001, 84:3-10.
35. Crocker P.R., Gordon S. Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages. J. Exp. Med. 1986, 164:1862-1875.
36. Schnaar R.L., Collins B.E., Wright L.P., Kiso M., Trobak M.B., Roder J.C., Crocker P.R. Myelin-associated glycoprotein binding to gangliosides: structural specificity and functional implications. Ann. NY Acad. Sci. 2006, 845:92-105.
37. Yang L.J., Zeller C.B., Shaper N.L., Kiso M., Hasegawa A., Shapiro R.E., Schnaar R.L. Gangliosides are neuronal ligands for myelin-associated glycoprotein. Prot. Natl. Acad. Sci. USA 1996, 93:814-818.
38. Zamze S., Harvey D.J., Pesheva P., Mattu T.S., Schachner M., Dwek R.A., Wing D.R. Glycosylation of a CNS-specific extracellular matrix glycoprotein, tenascin-R, is dominated by O-linked sialylated glycans and "brain-type" neutral N-glycans. Glycobiology 1999, 9:823-831.
39. Nakamura K., Yamaji T., Crocker P.R., Suzuki A., Hashimoto Y. Lymph node macrophages, but not spleen macrophages, express high levels of unmasked sialoadhesin: implication for the adhesive properties of macrophages in vivo. Glycobiology 2002, 12:209-216.
40. Demoy M., Gibaud S., Andreux J.P., Weingarten C., Gourtin B., Couvrer P. Splenic trapping of nanoparticles: complementary approaches for in situ studies. Pharm. Res. 1997, 14:463-468.
41. Ikezumi Y., Suzuki T., Hayafuji S., Okubo S., Nikolic-Paterson D.J., Kawachi H., Shimizu F., Uchiyama.M. The sialoadhesin (CD169) expressing a macrophage subset in human proliferative glomerulonephritis. Nephrol. Dial. Transplant. 2005, 20:2704-2713.
42. Hartnell A., Steel J., Turley H., Jones M., Jackson D.G., Crocker P.R. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 2001, 97:288-296.
43. Manil L., Davin J.C., Duchenne C., Kubiak C., Foidart J., Couvreur P., Mahieu P. Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro. Pharm. Res. 1994, 11:1160-1165.
44. Frei K., Steger C., Samorapoompichit P., Lucas T., Forster O. Expression and function of sialoadhesin in rat alveolar macrophages. Immunol. Lett. 2000, 71:167-170.